BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed CELZ catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:4f7986aed187483f4525@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:CELZ P1/P2 readout (est.): ADAPT
DESCRIPTION:Safety\, Tolerability\, and Effectiveness of Intramuscular Inje
 ction of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain\nNCT060
 53242 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Creative Medical 
 Technology Holdings Inc\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker CELZ (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT06053242\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06053242
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9a32485126a2f9a8e4e7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CELZ P1/P2 readout (est.): CREATE-1
DESCRIPTION:Safety and Efficacy of CELZ-201 in Patients With Recent Onset T
 ype 1 Diabetes\nNCT05626712 | PHASE1/PHASE2 | RECRUITING | sponsor: Creati
 ve Medical Technology Holdings Inc\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nTicker CELZ (confidence 0.9)\nSour
 ce: https://clinicaltrials.gov/study/NCT05626712\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05626712
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
